Loss expression of active fragile sites genes associated with the severity of breast epithelial abnormalities

Wang, Tiantian; Frezza, Eldo E.; Ma, Rong; Hu, Sanyuan; Liu, Chongzhong; Wachtel, Mitchell S.; Lü, Xiaomei; Feng, Jinzhou; Lu, Cuixia

doi:10.1097/00029330-200810020-00004

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WWOX and FHIT genes are located in active fragile sites and reduction in expression of both has been associated with development of breast cancer. Wang et al 2008 evaluated mRNA and protein expression for these gene products in breast tissue with normal histological appearances, atypical ductal hyperplasia, ductal carcinoma in situ, and invasive cancer. Compared with in situ and invasive cancer specimens, both normal and atypical hyperplasia specimens had greater rates of mRNA and protein expression; that is, expression of FHIT and WWOX decreased along with breast tissue progress from a normal histological appearance to atypical ductal hyperplasia, in situ cancer, and invasive cancer.…”

Section: The Gene and Epigenementioning

confidence: 99%

Pathology and biology associated with the fragile FHIT gene and gene product

Saldivar¹,

Shibata²,

Huebner³

2010

J of Cellular Biochemistry

View full text Add to dashboard Cite

More than 12 years and >800 scientific publications after the discovery of the first gene at a chromosome fragile site, the FHIT gene at FRA3B, there are still questions to pursue concerning the selective advantage conferred to cells by loss of expression of FHIT, the most frequent target of allele deletion in precancerous lesions and cancers. These questions are considered in light of recent investigations of genetic and epigenetic alterations to the locus and in a retrospective consideration of biological roles of the Fhit protein discovered through functional studies.

show abstract

Section: The Gene and Epigenementioning

confidence: 99%

Pathology and biology associated with the fragile FHIT gene and gene product

Saldivar¹,

Shibata²,

Huebner³

2010

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

Molecular profile of atypical hyperplasia of the breast

Danforth

2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Atypical ductal and atypical lobular hyperplasia (AH) of the breast are important proliferative lesions which are associated with a significantly increased risk for breast cancer. The breast cancer which develops in association with AH may occur synchronously, representing local progression, or metachronously at a later date in either the ipsilateral or contralateral breast. These high-risk characteristics of AH suggest they contain significant genomic changes. Methods To define the genomic changes in AH, a comprehensive review of the literature was conducted to identify the numerical chromosomal and structural chromosomal changes, DNA methylation, and gene expression abnormalities in atypical ductal and atypical lobular hyperplasia. Results AHs are characterized by advanced genomic changes including aneuploidy, loss of heterozygosity, gross chromosomal rearrangements such as amplifications and large-scale deletions, DNA methylation of tumor suppressor and other genes, and gene expression differences between AH and surrounding normal breast tissue including significant estrogen receptor expression. Many of these changes are shared by an associated synchronous breast cancer, consistent with an important precursor role for AH. At the same time, many of the genomic changes of AHs are also shared by common sporadic breast cancer, consistent with a high risk for future development of metachronous breast cancer. Conclusions This molecular profile should help clarify the genomic characteristics and malignant predisposition of AH, and aid in the identification of new targets for the prevention of breast cancer

show abstract